Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Salicylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.95 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.95 |
| ▸ | HPGD | P15428 | 6/20 | 0.95 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.95 |
| ▸ | CA12 | O43570 | 2/20 | 0.95 |
| ▸ | CA1 | P00915 | 2/20 | 0.95 |
| ▸ | CA2 | P00918 | 2/20 | 0.95 |
| ▸ | CA7 | P43166 | 2/20 | 0.95 |
| ▸ | CA9 | Q16790 | 2/20 | 0.95 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.95 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.95 |
| ▸ | CA4 | P22748 | 1/20 | 0.95 |
| ▸ | CA6 | P23280 | 1/20 | 0.95 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.95 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | G6PD | P11413 | 1/20 | 0.58 |
| ▸ | CASP7 | P55210 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salicylic Acid SCHEMBL28028722 | 1.00 | ALDH1A1 (0.95) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL31665922 | 1.00 | ALDH1A1 (0.95) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL10385490 | 0.97 | ALDH1A1 (0.90) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL29606432 | 0.97 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL29362663 | 0.97 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL29360246 | 0.97 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL1509155 | 0.97 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL17156443 | 0.97 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL8433746 | 0.97 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL1967 | 0.97 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4444431-A1 | SULFATE FREE PERSONAL CLEANSING COMPOSITION COMPRISING EFFECTIVE PRESERVATION | The Procter & Gamble Company (US) | 2024-10-16 | — | — | EP | claimed |
| CN-118265516-A | Sulfate-free personal cleansing compositions with effective preservation | 宝洁公司 | 2024-06-28 | — | — | CN | claimed |
| US-20230190606-A1 | SULFATE FREE PERSONAL CLEANSING COMPOSITION COMPRISING EFFECTIVE PRESERVATION | THE PROCTER & GAMBLE COMPANY | 2023-06-22 | — | — | US | claimed |
| WO-2023108097-A1 | SULFATE FREE PERSONAL CLEANSING COMPOSITION COMPRISING EFFECTIVE PRESERVATION | THE PROCTER & GAMBLE COMPANY (US) | 2023-06-15 | — | — | WO | claimed |
| US-20080020059-A1 | COMPOSITIONS AND METHODS FOR TOPICAL TREATMENT OF SKIN INFECTION | CHIOU CONSULTING, INC. (US) | 2008-01-24 | — | — | US | claimed |
| US-20060205615-A1 | Additives and lubricant formulations for improved antioxidant properties | AFTON CHEMICAL CORPORATION | 2006-09-14 | — | — | US | claimed |
| WO-2005055927-A2 | COMPOSITIONS AND METHODS FOR TOPICAL TREATMENT OF SKIN INFECTION | CHIOU CONSULTING INC. (US) | 2005-06-23 | — | — | WO | claimed |
| US-20050123620-A1 | Compositions and methods for topical treatment of skin infection | CHIOU CONSULTING, INC. | 2005-06-09 | — | — | US | claimed |
| EP-4423168-B1 | POLYETHER POLYMERIZATION PROCESS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-12-10 | — | — | EP | disclosed |
| US-12458575-B2 | Sulfate free personal cleansing composition comprising effective preservation | THE PROCTER & GAMBLE COMPANY (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250241833-A1 | SULFUR CO-GRINDING PROCESS | THE PROCTER & GAMBLE COMPANY | 2025-07-31 | — | — | US | disclosed |
| CN-119499129-A | Personal care composition preservative level optimization | 宝洁公司 | 2025-02-25 | — | — | CN | disclosed |
| US-12201971-B2 | Polyether polymerization process | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240392068-A1 | POLYETHER POLYMERIZATION PROCESS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2024-11-28 | — | — | US | disclosed |
| WO-2002022104-A2 | TREATED SUBSTRATE WITH IMPROVED TRANSFER EFFICIENCY OF TOPICAL APPLICATION | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2002-03-21 | — | — | WO | disclosed |
| EP-0330697-A4 | PREPARATION OF ABO 3? COMPOUNDS FROM MIXED METAL AROMATIC COORDINATION COMPLEXES | — | 1991-06-05 | — | — | EP | disclosed |
| US-4946810-A | Preparation of ABO3 compounds from mixed metal aromatic coordination complexes | THE DOW CHEMICAL COMPANY (US) | 1990-08-07 | — | — | US | disclosed |
| US-4880758-A | FORMING A POWDER BY DECOMPOSING A COMPLEX OF A METAL A COMPOUND, A METAL B COMPOUND, A SOLVATE, AN ALCOHOL AND A DISUBSTITUTED AROMATIC COMPOUND | THE DOW CHEMICAL COMPANY (US) | 1989-11-14 | — | — | US | disclosed |
| EP-0330697-A1 | PREPARATION OF ABO 3? COMPOUNDS FROM MIXED METAL AROMATIC COORDINATION COMPLEXES | THE DOW CHEMICAL COMPANY (US) | 1989-09-06 | — | — | EP | disclosed |
| WO-1989001922-A1 | PREPARATION OF ABO3 COMPOUNDS FROM MIXED METAL AROMATIC COORDINATION COMPLEXES | THE DOW CHEMICAL COMPANY (US) | 1989-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190606-A1 | SULFATE FREE PERSONAL CLEANSING COMPOSITION COMPRISING EFFECTIVE PRESERVATION | PRSS3, PLP2, PRSS2 | ALDH1A1 3763/4885KDM4E 2496/4885HPGD 2252/4885 |
| US-12458575-B2 | Sulfate free personal cleansing composition comprising effective preservation | PRSS3, PLP2, PRSS2 | ALDH1A1 3763/4885KDM4E 2496/4885HPGD 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.